Andrew Robell
Corporate Officer/Principal bei Phase 2 Discovery, Inc.
Ursprung des Netzwerks ersten Grades von Andrew Robell
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.
4
| Private Company | Pharmaceuticals: Major | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Andrew Robell
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
University of Cincinnati (Ohio) | College/University | Corporate Officer/Principal | |
Villanova University | College/University | Graduate Degree | |
University of Pennsylvania | College/University | Doctorate Degree | |
MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Aventis, Inc. | Corporate Officer/Principal | ||
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
RxDino LLC
RxDino LLC Pharmaceuticals: MajorHealth Technology RxDino LLC operates as a dermatology pharmaceutical company. The firm develops skin products for the treatment of dermatitis, rash, eczema, itchy, irritated skin, and allergies to plants and chemicals, such as poison ivy. It provides Over-the-counter topical hydrocortisone ointment with a formulation containing dehydroepiandrosterone as an emollient that enables hydrocortisone to be effective. The company is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Founder | |
ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
Organon NV
Organon NV Pharmaceuticals: MajorHealth Technology N.V. Organon engages in the development, manufacture, and sale of prescription medicines. It offers products for cardiovascular diseases, fertility, gynecology, anesthesia, respiratory, consumer health care, neuroscience as well as immunology, animal health, and oncology. Its products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. The company was founded in 1923 and is headquartered in Oss, the Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistik
International
Vereinigte Staaten | 9 |
Vereinigtes Königreich | 2 |
Niederlande | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 4 |
Operativ
Corporate Officer/Principal | 7 |
Director/Board Member | 2 |
Chairman | 1 |
President | 1 |
Chief Executive Officer | 1 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Andrew Robell
- Unternehmensverbindungen